Kura Oncology (NASDAQ:KURA) Given Market Outperform Rating at JMP Securities

Kura Oncology (NASDAQ:KURA - Get Free Report)'s stock had its "market outperform" rating reiterated by equities research analysts at JMP Securities in a research report issued on Monday, Benzinga reports. They currently have a $32.00 target price on the stock. JMP Securities' price target suggests a potential upside of 52.31% from the company's previous close.

Other equities research analysts also recently issued reports about the stock. StockNews.com downgraded shares of Kura Oncology from a "hold" rating to a "sell" rating in a research note on Monday, April 15th. HC Wainwright reaffirmed a "buy" rating and set a $32.00 target price on shares of Kura Oncology in a research note on Friday. Finally, Wedbush reaffirmed an "outperform" rating and set a $37.00 target price on shares of Kura Oncology in a research note on Friday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company. According to MarketBeat, Kura Oncology has an average rating of "Moderate Buy" and a consensus target price of $28.28.

Kura Oncology Trading Up 1.8 %

NASDAQ:KURA traded up $0.38 on Monday, hitting $21.01. The stock had a trading volume of 813,820 shares, compared to its average volume of 1,280,384. The company has a quick ratio of 16.67, a current ratio of 16.67 and a debt-to-equity ratio of 0.02. The stock has a market cap of $1.60 billion, a price-to-earnings ratio of -9.68 and a beta of 0.89. The company has a fifty day moving average price of $20.66 and a two-hundred day moving average price of $16.13. Kura Oncology has a 1-year low of $7.41 and a 1-year high of $24.17.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.03). Kura Oncology's revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.50) EPS. Equities research analysts expect that Kura Oncology will post -2.35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kura Oncology

A number of large investors have recently bought and sold shares of KURA. Deerfield Management Company L.P. Series C lifted its stake in shares of Kura Oncology by 35.1% in the third quarter. Deerfield Management Company L.P. Series C now owns 4,374,044 shares of the company's stock valued at $39,891,000 after purchasing an additional 1,136,044 shares during the period. BVF Inc. IL lifted its stake in shares of Kura Oncology by 9.5% in the fourth quarter. BVF Inc. IL now owns 7,373,228 shares of the company's stock valued at $106,027,000 after purchasing an additional 642,245 shares during the period. Verition Fund Management LLC acquired a new stake in shares of Kura Oncology in the fourth quarter valued at about $6,695,000. Vanguard Group Inc. raised its position in Kura Oncology by 7.5% during the third quarter. Vanguard Group Inc. now owns 3,924,448 shares of the company's stock worth $35,791,000 after acquiring an additional 275,173 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in Kura Oncology by 10.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,001,754 shares of the company's stock worth $28,785,000 after acquiring an additional 197,530 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.